Sign in Subscribe
Kelly Ke

Kelly Ke

Mar
05
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List

China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List

Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
5 min read
Feb
12
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines

NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines

The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
4 min read
Feb
05
Pioneering Value-Based Care in China: A Conversation with Dr. Felix Lee, Co-CEO of The GBA Healthcare Group

Pioneering Value-Based Care in China: A Conversation with Dr. Felix Lee, Co-CEO of The GBA Healthcare Group

This success story emphasizes the importance of aligning healthcare innovation with a nation's infrastructure and social security framework to ensure practical, scalable, and sustainable care delivery and payment models.
15 min read
Jan
02
The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations

The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations

These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
9 min read
Dec
04
NHSA Strengthens Control Over Outpatient Spending

NHSA Strengthens Control Over Outpatient Spending

Effectively navigating these regulatory changes will have significant and lasting implications for drug manufacturers, particularly in shaping their pricing strategies, reimbursement models, and distribution channel approaches in China.
7 min read
Nov
06
Advances in New Technology Add-On Payments for Innovative Medicine in China’s DRG/DIP Framework

Advances in New Technology Add-On Payments for Innovative Medicine in China’s DRG/DIP Framework

In July, China’s National Healthcare Security Administration introduced the CHS-DRG Grouping Plan (Version 2.0), expanding the number of
5 min read
Oct
02
Capitalizing on Specialized Medical Services in China: Opportunities for Innovative Life Sciences Manufacturers

Capitalizing on Specialized Medical Services in China: Opportunities for Innovative Life Sciences Manufacturers

To take advantage of these opportunities, manufacturers must focus on three key success factors.
6 min read
Aug
28
Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China

Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China

Understanding and strategically applying these trends is crucial for optimizing pricing strategies and enhancing market adoption of innovative medical technologies in China.
7 min read
Jul
10
5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment

5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment

In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
4 min read
Jul
03
NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items

NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items

Executive Summary In China, both public and private not-for-profit hospitals are required to adhere to the Medical Service Pricing Catalogs
5 min read